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Background: The dysregulation of transforming growth factor-β (TGF-β) signaling plays a crucial role in ovarian
carcinogenesis and in maintaining cancer stem cell properties. Classified as a member of the ATP-binding cassette
(ABC) family, ABCA1 was previously identified by methylated DNA immunoprecipitation microarray (mDIP-Chip) to
be methylated in ovarian cancer cell lines, A2780 and CP70. By microarray, it was also found to be upregulated in
immortalized ovarian surface epithelial (IOSE) cells following TGF-β treatment. Thus, we hypothesized that ABCA1
may be involved in ovarian cancer and its initiation.
Results: We first compared the expression level of ABCA1 in IOSE cells and a panel of ovarian cancer cell lines and
found that ABCA1 was expressed in HeyC2, SKOV3, MCP3, and MCP2 ovarian cancer cell lines but downregulated in
A2780 and CP70 ovarian cancer cell lines. The reduced expression of ABCA1 in A2780 and CP70 cells was associated
with promoter hypermethylation, as demonstrated by bisulfite pyro-sequencing. We also found that knockdown of
ABCA1 increased the cholesterol level and promoted cell growth in vitro and in vivo. Further analysis of ABCA1
methylation in 76 ovarian cancer patient samples demonstrated that patients with higher ABCA1 methylation are
associated with high stage (P = 0.0131) and grade (P = 0.0137). Kaplan-Meier analysis also found that patients with
higher levels of methylation of ABCA1 have shorter overall survival (P = 0.019). Furthermore, tissue microarray using
55 ovarian cancer patient samples revealed that patients with a lower level of ABCA1 expression are associated with
shorter progress-free survival (P = 0.038).
Conclusions: ABCA1 may be a tumor suppressor and is hypermethylated in a subset of ovarian cancer patients.
Hypermethylation of ABCA1 is associated with poor prognosis in these patients.
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Ovarian cancer is the most lethal tumor in women and
the second most frequent gynecological malignancy [1].
As ovarian cancer has few symptoms early in its course,
patients are generally diagnosed with advanced-stage
tumors. Despite advances in chemotherapy, the poor* Correspondence: hclai@s.tmu.edu.tw; biowyc@ccu.edu.tw
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reflected by the 5-year survival rate of less than 20% [2].
Current prognostic indicators using clinicopathological
variables, including stage and grade, neither accurately
predict clinical outcomes nor provide biological insight
into the disease. Thus, a better understanding of the mo-
lecular changes in ovarian cancer would provide insight
for better diagnosis and prognosis of this deadly disease.
The transforming growth factor-β (TGF-β) signaling
pathway plays an important role in the regulation of
ovarian growth [3]. During ovulation, the ovarian surface
epithelial (OSE) cell covering the ovary undergoeshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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growth is inhibited by TGF-β, which plays a key role in
preventing overproliferation of OSE cells [4]. In this re-
gard, the dysregulation of TGF-β signaling may be an
early step in the development of epithelial ovarian can-
cer. This is in agreement with the observation that re-
sistance to TGF-β signaling is commonly seen in ovarian
cancer, suggesting that reduced responsiveness to TGF-β
is a key event in ovarian cancer [5].
Epigenetic alterations, including DNA methylation and
histone modifications, play an important role in control-
ling gene expression [6,7]. Moreover, in cancer, aberrant
epigenetic modifications are frequently found to be re-
sponsible for the silencing of tumor suppressor genes.
Our previous studies using genome-wide techniques
have identified several direct targets of TGF-β in immor-
talized ovarian surface epithelial (IOSE) cells [8]. These
targets are silenced epigenetically in ovarian cancer and
are associated with poor prognosis in ovarian cancer pa-
tients [9-11]. Restoration of the genes inhibited tumor
growth, thus suggesting that they are tumor suppressors.
In order to identify additional genes that are hyper-
methylated in ovarian cancer, we performed methylated
DNA immunoprecipitation microarray (mDIP-Chip) in
IOSE cells and a panel of ovarian cancer cell lines. Our
result showed that ABCA1, which is upregulated by
TGF-β [8] and is a major regulator of cellular cholesterol
[12], is hypermethylated in a subset of ovarian cancer
cell lines. Further analysis demonstrated that ABCA1
methylation was associated with poor prognosis in ovar-
ian cancer patients. These results suggested that ABCA1
may be a tumor suppressor and can serve as a prognos-
tic indicator in ovarian cancer.
Results
ABCA1 is epigenetically silenced in ovarian cancer cells
Our previous studies demonstrated that novel TGF-β
targets, FBXO32 and RunX1T1, are epigenetically si-
lenced by promoter hypermethylation in ovarian cancer
[10,11]. To identify additional genes regulated by TGF-β
that exhibited promoter hypermethylation in ovarian
cancer, we performed mDIP-Chip in IOSE cells and a
panel of ovarian cancer cell lines [13]. One of the genes,
ABCA1, which exhibited promoter methylation in a sub-
set of ovarian cancer cell lines but not in IOSE cells, was
selected for further analysis. This gene was also previ-
ously found to be upregulated in IOSE cells after TGF-β
treatment [8].
To confirm our microarray result, we first examined
the mRNA expression level of ABCA1 in various ovarian
cancer cell lines (Figure 1A). The result showed that
ABCA1 was repressed in A2780 and CP70 cells. Al-
though treatment of HDAC inhibitor (TSA) or EZH2 in-
hibitor (GSK343) alone did not result in any significantre-expression of ABCA1, treatment of demethylating
agent, 5aza, alone resulted in a robust re-expression of
ABCA1 in CP70 ovarian cancers, suggesting that DNA
methylation is responsible for the suppression of ABCA1
in CP70 cells (Figure 1B). These results were confirmed
by bisulfite pyro-sequencing such that CpG sites around
the transcriptional start site (TSS) of ABCA1 were heav-
ily methylated in A2780 and CP70 ovarian cancer cells,
while such methylation was either undetectable or low
in IOSE cells or other ovarian cancer cells (Figure 1C).
Taken together, these results suggested that promoter
hypermethylation may be responsible for the transcrip-
tional repression of ABCA1 in ovarian cancer.Depletion of ABCA1 increases cholesterol level in ovarian
cancer cells
As ABCA1 is responsible for cholesterol efflux, we first
measured the effect of ABCA1 depletion on the choles-
terol level of ovarian cancer cells. Lentiviral knockdown of
ABCA1 was performed in MCP3 (Figure 2A) and HeyC2
(Figure 2B) ovarian cancer cells. The result showed that
more than 50% repression of ABCA1 was observed in
these cells. As expected, depletion of ABCA1 resulted
in a significant accumulation of cholesterol in MCP3
(Figure 3A, P < 0.05) and HeyC2 (Figure 3B, P < 0.05)
cells.Depletion of ABCA1 promotes cell growth in ovarian
cancer cells in vitro and in vivo
Dysregulation of cholesterol homeostasis has been shown
to be related to cancer. Therefore, we hypothesized that
ABCA1 might act as a tumor suppressor in ovarian can-
cer. To confirm this hypothesis, we examined the effect of
ABCA1 depletion on the growth of ovarian cancer cells.
Interestingly, depletion of ABCA1 resulted in an increased
cell growth in MCP3 (Figure 2C, P < 0.001) and HeyC2
(Figure 2D, P < 0.05) cells as demonstrated by colony for-
mation assay. Further in vivo experiments also demon-
strated that significant increased tumor growth was
observed in ABCA1-depleted HeyC2 cells as compared to
control (Figure 3C).Hypermethylation of ABCA1 associates with tumor
progression in ovarian cancer patients
Having demonstrated that promoter hypermethylation
of ABCA1 can be observed in ovarian cancer cell lines,
we then proceeded to examine if such epigenetic event
can also be observed in ovarian cancer patient samples
(Table 1, Figure 4A, B). Results from bisulphite pyro-
sequencing showed that patients with a higher stage
(P = 0.026) and grade (P = 0.013) but not age have a sig-
nificantly higher level of ABCA1 methylation.
A B
C
Figure 1 ABCA1 expression and methylation level in IOSE cells and ovarian cancer cell lines. (A) Total RNA was isolated from ovarian cells
and converted into cDNA for amplification with specific primers for ABCA1. The relative level of expression after quantitative real-time RT-PCR was
compared to IOSE cells (set as one fold). Each bar represents mean ± SD. (B) CP70 cells were treated with TSA (0.5 μM, 12 h), GSK343 (1 μM, 3 days), or
5aza (0.5 μM, 3 days). The expression level of ABCA1 was determined by RT-PCR. Treatment of 5aza, but not TSA or GSK, resulted in robust
re-expression of ABCA1 in CP70 cells. Each bar represents mean ± SD. (C) The methylation status of the ABCA1 promoter and TSS region was
analyzed by bisulfite pyro-sequencing from −90 to +190 (black line underneath). The upper panel shows the ABCA1 promoter and TSS region
and the corresponding CpG sites (vertical bar), and the lower panel illustrates DNA methylation at the interrogated CpG site (circle) in IOSE
cells, two NOSE samples, and ovarian cancer cell lines with intensity of gray color indicating methylation level.
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prognosis in ovarian cancer patients
To further investigate if ABCA1 methylation was predict-
ive of survival in ovarian cancer patients, we performed
Kaplan-Meier survival analyses. Using the baseline methy-
lation level of ABCA1 in IOSE cells (3%) as a cutoff, a sig-
nificant association between patients with high ABCA1
methylation and shorter overall survival (OS; P = 0.019)
but not progression-free survival (PFS; P = 0.1) was ob-
served (Figure 4C, D).
Because the above approaches based on a cutoff value
may have biased the data analysis, the Cox proportional
hazards model was used to analyze the predictive value
of ABCA1 methylation and other clinicopathological pa-
rameters on OS and PFS (Table 2). As expected, a higher
stage (OS: hazard ratio: 11.321, P = 0.02; PFS: hazard ra-
tio: 14.278, P < 0.01) and grade (OS: hazard ratio: 22.559,P = 0.03; PFS: hazard ratio: 20.586, P < 0.01) but not age
was significantly associated with poor prognosis. Inter-
estingly, methylation of ABCA1 is also associated with
poor patient outcome in ovarian cancer (OS: hazard ra-
tio: 1.106, P = 0.033; PFS: hazard ratio: 1.096, P = 0.013).
However, this association was not observed in multivari-
ate analysis, thus suggesting that other factors are also
involved in the survival of ovarian cancer patients
(Table 3). Taken together, methylation of ABCA1 is par-
tially associated with poor prognosis in ovarian cancer
patients.
Low expression of ABCA1 associates with poor prognosis
in ovarian cancer patients
To further investigate the association between expression
of ABCA1 and survival of ovarian cancer patients, we per-




Figure 2 Effects of ABCA1 knockdown on cell growth. Real-time RT-PCR expression of ABCA1 in (A) MCP3 and (B) HeyC2 cells infected by
lentivirus against shGFP (control) or shABCA1. Each bar represents mean ± SD. The growth of ABCA1 knockdown (C) MCP3 and (D) HeyC2 cells
was examined by soft agar assay. Quantitative analysis of the soft agar assay is also shown. ***P < 0.001; *P < 0.05.
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expression of ABCA1 is not associated with any clinico-
pathological parameters of the samples (Table 5), patients
with low expression of ABCA1 are associated with shorter
progression-free survival (Figure 5B). Similarly, analysis of
TCGA ovarian cancer RNA-Seq dataset [14] also found
that patients with lower expression of ABCA1 are associ-
ated with shorter overall survival (Figure 5C).
Discussion
In the current study, we demonstrated promoter hyper-
methylation of ABCA1, a cholesterol transporter in ovar-
ian cancer cell lines and patient samples. This is a
cancer-specific event as methylation of ABCA1 was not
observed in IOSE and normal ovarian surface epithelial(NOSE) cells. Methylation of ABCA1 was also negatively
associated with its expression and increased cell growth
in vitro and in vivo. Importantly, ovarian cancer patients
with higher ABCA1 methylation were associated with
shorter survival. Result from tissue microarray and TCGA
ovarian cancer RNA-Seq dataset also demonstrated that
ovarian cancer patients with lower ABCA1 expression
were associated with shorter survival. Our results were
also confirmed by a recent finding that ABCA1 is
epigenetically silenced by promoter methylation in
prostate cancer cells. Hypermethylation of ABCA1 is
associated with high-grade prostate cancer [15]. Taken
together, these results suggest that ABCA1 may be a




Figure 3 Effects of ABCA1 knockdown on cholesterol level and ovarian cancer growth in vivo. The cholesterol level of ABCA1 knockdown
(A) MCP3 and (B) HeyC2 cells was measured by cholesterol quantitation assay. (C) The effect of ABCA1 knockdown on tumor growth in vivo was
determined by the nude mice model. HeyC2 cells stably infected with shABCA1 (red arrow) or shGFP (green arrow) were injected subcutaneously
into athymic nude mice. One week later, tumor volumes were measured daily. From day 19, the volume of tumors with ABCA1 knockdown was
significantly reduced as compared to vector controls (*P < 0.05; **P < 0.005). Data were expressed as mean ± SD (n = 3).
Table 1 Association between methylation of ABCA1 and
clinicopathological features of 76 ovarian cancer patients
Methylation % P
Age
≧60 5.2 ± 3.01a (53/76)b 0.379
<60 6.71 ± 5.34 (23/76)
Stagec
Low 4.36 ± 2.10 (27/76)
High 6.52 ± 4.44 (49/76) 0.026e
Graded
Low 4.71 ± 3.62 (29/76)
High 6.26 ± 3.77 (47/76) 0.013
aMean ± SD.
bNumber in parentheses represents the number of cases.
cLow and high stages are defined as FIGO I and II and FIGO III and IV,
respectively.
dLow and high grades are defined as grade 1–2 and grade 3, respectively.
eItalicized value indicates P < 0.05.
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(ABC) protein family, is responsible for cholesterol ef-
flux and metabolism. It has been shown to be essential
for the synthesis of high-density lipoprotein (HDL) parti-
cles by exporting cellular cholesterol out of the cell. Re-
cent studies suggested that ABCA1 may be a tumor
suppressor [16]. For example, Smith and Land demon-
strated that overexpression of ABCA1 in colon cancer
cells resulted in a decrease of cellular cholesterol and in-
hibition of tumor growth in vitro and in vivo. This
growth inhibition may be due to apoptosis, as overex-
pression of ABCA1 enhanced cytochrome C release
from mitochondria.
Expression of ABCA1 has been previously shown to be
activated by the nuclear receptor liver X receptor (LXR)
[17]. Interestingly, TGF-β could significantly increase the
expression of ABCA1 through activation of LXR signaling
[18]. Together with our previous finding that ABCA1 is a
TGF-β target in IOSE cells, it is thus suggested that the
growth inhibitory effect of TGF-β may be partly due to
overexpression of ABCA1 in IOSE cells. Epigenetic alter-
ation of ABCA1 may contribute to the resistance of TGF-
β-mediated growth suppression in ovarian cancer cells [9].
A B
C D
Figure 4 Association between ABCA1 methylation and tumor progression. Dot plot showing the association between ABCA1 methylation in
different (A) stages and (B) grades in 76 ovarian cancer patient samples. Methylation of ABCA1 was determined by bisulfite pyro-sequencing. Low
stage and low grade represented FIGO I and II and grade 1–2, respectively. While high stage and high grade represented FIGO III and IV and grade 3,
respectively. *P < 0.05 by the Mann-Whitney U test. Kaplan-Meier analysis of ABCA1 methylation for (C) progression-free survival and (D) overall survival
in 76 ovarian cancer patient samples is shown. Patients were grouped according to methylation of ABCA1 of 3%, which is based on the methylation
level of IOSE cells. Patients with “high” ABCA1 methylation (>3% methylation) have significant shorter overall survival (P = 0.019) but not
progression-free survival than patients with “low” ABCA1 methylation. Log-rank P values are shown.
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known to be related to cancer [19]. Several studies have
demonstrated an elevated level of cholesterol in tumor
as compared to normal tissue [20,21]. Recently, Li et al.
also demonstrated that ovarian cancer patients with
higher serum low-density lipoprotein (LDL) level were sig-
nificantly associated with shorter progression-free survival
and overall survival [22]. It may be due to the fact that
lipid serves as an energy source for promoting cell growth
and metastasis in ovarian cancer [23]. In this regard,
numerous studies have demonstrated that cholesterol-
lowering agents, such as statins, exhibit anti-tumorTable 2 Univariable analysis of survival by the Cox proportio
Variable Overall survival
HR (95% CI)




aItalicized value indicates P < 0.05.activity against various cancers [24]. For example, statins
have been shown to reduce tumor growth in xenograft
models [25,26]. In ovarian cancer, a clinical study demon-
strated that patients with statins are associated with im-
proved survival [27]. This may be due to the growth
inhibition and augmentation of apoptosis by statins in
ovarian cancer cells [28-30]. Furthermore, inhibition of
HMG-CoA reductase by statins can also lead to a de-
creased level of mevalonate, which is important for the
synthesis of isoprenoids including geranyl pyrophosphate
(GPP) and farnesyl pyrophosphate (FPP) [24,31]. Proper
activation of several signaling molecules such as smallnal hazards model
Progression-free survival
P HR (95% CI) P
0.033a 1.096 (1.020–1.179) 0.013
0.187 1.309 (0.579–2.963) 0.518
0.02 14.278 (4.233–48.154) <0.01
0.03 20.586 (4.817–87.977) <0.01
Table 3 Multivariate analysis of survival by the Cox proportional hazards model
PFS OS
HR (95% CI) P HR (95% CI) P
ABCA1 methylation 1.013 (0.960–1.069) 0.636 1.016 (0.965–1.069) 0.554
Age 0.993 (0.961–1.025) 0.665 1.019 (0.988–1.051) 0.233
Stage 1.633 (1.159–2.302) 0.005 2.330 (1.196–4.538) 0.013
Grade 1.578 (0.557–4.473) 0.390 1.538 (0.340–6.963) 0.577
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GPP and FPP. Thus, blocking of cholesterol metabolism
would reduce cancer growth by suppression of the proli-
feration signal.
Conclusions
Promoter methylation of ABCA1 was observed in ovar-
ian cancer cell lines and patient samples. Ovarian cancer
patients with higher methylation and lower expression
of ABCA1 were associated with shorter survival. The




Seventy-six treatment-naive ovarian cancer samples were
obtained from Tri-Service General Hospital, Taipei, Taiwan
(Table 6). Eight NOSE cell samples were acquired from
patients during surgery for benign gynecological disease atTable 4 Summary of clinicopathological data of 55
ovarian cancer patients in tissue microarray
Ovarian cancer (n = 55)


















PFS progression-free survival, OS overall survival.either the Tri-Service General Hospital or Indiana Univer-
sity, USA. For this cohort of ovarian cancer patient sam-
ples, the median age at the time of diagnosis was 54 years
(range, 18–90 years). Forty-nine cases (64.5%) were high
stage (International Federation of Gynecology and Obstetrics
(FIGO) stages III and IV), and 27 cases (35.5%) were low
stage (FIGO stages I and II). Forty-seven cases (61.8%)
were grade III, 13 cases (17.1%) were grade I, and 16 cases
(21.1%) were grade II. All of the studies involving human
ovarian epithelial samples were approved by the institu-
tional review boards of the Tri-Service General Hospital,
Taiwan, and Indiana University.
Cell culture
IOSE cells were derived by transducing the catalytic subunit
of human telomerase and the papilloma virus subunit E7
into primary ovarian epithelial cells, as described previously
[32]. The cells were maintained in a 1:1 mixture of Medium
199 (Sigma, St. Louis, MO) and 105 (Sigma) supplemented
with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad,
CA), 400 ng/ml hydrocortisone (Sigma), 10 ng/ml EGF, and
50 units/ml of penicillin/streptomycin (Invitrogen). The
ovarian cancer cell lines A2780, CP70, MCP2, and MCP3
were propagated in RPMI 1640 (Invitrogen) containing
10% FBS. HeyC2 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 5% FBS, 1% NEAA,
1% Gln, and 1% HEPES. SKOV3 cells were cultured in
McCoy’s 5A containing 10% FBS, 1% NEAA, 1% Gln, and
1% HEPES.
DNA extraction, RNA extraction, and quantitative reverse
transcription-PCR
DNA was extracted with the Tissue & Cell Genomic DNA
Purification Kit (GeneMark, Taiwan). It was eluted in 50
μl distilled water and stored at −20°C until use. Total RNA
from cell lines was extracted using TRIzol (Invitrogen), as
previously described. Briefly, 1 μg of total RNA was
treated with DNase I (amplification grade, Invitrogen) be-
fore first-strand cDNA synthesis using reverse transcrip-
tase (Superscript II RT, Invitrogen). The real-time PCR
reactions were carried out using the ABI StepOne real-
time PCR system (Applied Biosystems, Foster City, CA)
with specific primers (Additional file 1: Table S1). The
relative expression of ABCA1 was calculated using the
comparative Ct method.
AB C
Figure 5 Association between expression of ABCA1 and survival in ovarian cancer patients. Expression of ABCA1 in 55 ovarian cancer
patient samples was determined by IHC in tissue microarray. (A) Representative image of ovarian cancer showing high (left panel) and low (right
panel) ABCA1 expression on the cell membrane or cytoplasm (×400). (B) Kaplan-Meier analysis found that patients with low ABCA1 expression
have shorter progression-free survival than patients with high ABCA1 expression (P = 0.038). (C) Similar results can be observed in TCGA ovarian
cancer RNA-Seq dataset that patients with low expression of ABCA1 are associated with shorter overall survival (P = 0.0008). Log-rank P values
are shown.
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Bisulphite pyro-sequencing was performed as described
previously [11]. Briefly, 0.5 μg of genomic DNA was
bisulfite-modified using the EZ DNA Methylation Kit
(Zymo Research, Orange, CA), according to the manufac-
turer’s protocol. The bisulfite-modified DNA was subjectedTable 5 Association between expression of ABCA1 and
clinicopathological features of 55 ovarian cancer patients
Expression score
High expression Low expression
Age
≧60 11a (20%) 26 (47.2%)
<60 5 (9.1%) 13 (23.6%) 0.572
Stage
Low 6 (10.9%) 16 (29.1%)
High 10 (18.2%) 23 (41.8%) 0.528
Grade
Low 3 (5.5%) 6 (10.9%)
High 13 (23.6%) 33 (60%) 0.522
aNumber of cases.to PCR amplification using a tailed reverse primer in com-
bination with a biotin-labeled universal primer. The PCR
and sequencing primers were designed using PyroMark
Assay Design 2.0 (Qiagen GmbH, Hilden, Germany). The
ABCA1 TSS (−90 to +190) was PCR-amplified with spe-
cific primers (Additional file 1: Table S1) in a 25-μl reaction
containing 2× RBC SensiZyme Hotstart Taq premix (RBC
Bioscience, Taiwan). Prior to pyro-sequencing, 1.5 μl of
each PCR reaction was analyzed on 1% agarose gel. The
pyro-sequencing was performed on the PyroMark Q24 in-
strument (Qiagen) using the Pyro Gold Reagents (Qiagen),
according to the manufacturer’s protocol. The methylation
level of 11 CpG sites, which are located −13 to +95 with
respect to the TSS, was measured. The methylation per-
centage of each cytosine was determined using the fluo-
rescence intensity of cytosines divided by the sum of the
fluorescence intensity of cytosines and thymines at each
CpG site. In vitro methylated DNA (Millipore) was in-
cluded as positive control for pyro-sequencing.
Knockdown of ABCA1 by shRNA
The small hairpin RNA (shRNA) of ABCA1 were acquired
from the National RNAi Core Facility Platform at the
Table 6 Summary of clinicopathological data of 76
ovarian cancer patients
Ovarian cancer (n = 76)

















PFS progression-free survival, OS overall survival.
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Academia Sinica, Taiwan. Briefly, 293T cells were trans-
fected with shRNA (TRCN0000029093), pMDG, and
pCMVR 8.91 using the ProFection Mammalian Transfec-
tion System (Promega) to prepare the shABCA1 lentivirus.
Infected ovarian cancer cells were selected by incubating
with puromycin (2 μg/ml; Sigma) for at least 2 days.
Soft agar assay for colony formation
Trypsinized cells (1,000 cells) were seeded and mixed in
1.5 ml of 0.35% top layer agar supplemented with DMEM
with 10% FBS. This suspension was overlaid on the
bottom layer of 0.5% agar in DMEM with 10% FBS in a
six-well plate. Plates were allowed to solidify and then in-
cubated at 37°C for around 3 weeks. Colony formation
was monitored daily by microscopic observation. At the
end of the experiments, the plates were stained with iodo-
nitrotetrazolium (INT) stain (Sigma) for 48 h at 37°C. The
number of colonies was counted.
Immunohistochemical analysis on ovarian tissue
microarray
The paraffin-embedded ovarian cancer patients’ tissue
microarray were prepared and retrieved from the Depart-
ment of Pathology, Tri-Service General Hospital as de-
scribed previously [33]. The tissue microarray contained 55
samples of ovarian cancer patients (Table 4). The immuno-
histochemistry procedure followed a standard protocol,
using a rabbit polyclonal anti-human ABCA1 antibody(NB400-105, Novus Biologicals). All tissue microarray slides
were examined and scored by two pathologists. Immuno-
histochemistry (IHC) scoring was determined by distribu-
tion of positively stained cell × intensity of the staining. A
scoring of 60 was used as a cutoff value.
In vivo tumorigenicity assay
A total of three, 8-week-old, athymic nude mice (BALB/
cByJNarl) were obtained from the National Laboratory
Animal Center, Taiwan. All mice were kept under spe-
cific pathogen-free conditions using a laminar airflow
rack with free access to sterilized food and autoclaved
water. All experiments were performed under license
from Animal Experimentation Ethics Committee of the
National Chung Cheng University. HeyC2 cells (1 × 106)
stably infected with pLKO.1/shABCA1 or pLKO.1/shGFP
were re-suspended in 0.1 ml of medium and Matrigel (BD
Biosciences, San Jose, CA) mixture (1:1). The cell sus-
pension was then injected subcutaneously into the flank
of each mouse (day 0). Tumor size was measured daily
with calipers in length (L) and width (W). Tumor volume
was calculated using the formula (L ×W2/2). At the end
of the experiment, all mice were sacrificed by cervical
dislocation.
Analysis of cellular cholesterol content
Ovarian cancer cells (1 × 104) infected with shABCA1 or
shGFP were seeded in a six-well dish and cultured for 48 h.
After 48 h, the cells were washed with cold PBS twice and
scraped. The cells were re-suspended in 10% RIPA buffer
(50 mM HEPES-KOH, pKa 7.55, 500 mM LiCl, 1 mM
EDTA, 0.1% NP-40, and 0.07% Na-deoxycholate) and kept
on ice for 15 min. Cholesterol content was determined by
the Amplite™ Fluorimetric Cholesterol Quantitation Kit
(AAT Bioquest, Sunnyvale, CA) according to the manufac-
turer’s protocol. Fluorescence of cholesterol was detected
by Ex/Em at 540/590 nm.
Statistical analysis
PFS and OS were assessed by Kaplan-Meier analysis using
the log-rank test. Progression-free survival was defined as
the duration from the day of diagnosis or chemotherapy to
the detection of new lesions or progression of residual le-
sions. Overall survival was defined as the duration from the
day of diagnosis to death. A DNA methylation level at 3%,
which is the level of methylation in OSE cells, was used as
a cutoff. Fisher’s exact test or the Mann-Whitney U test
was also used to compare parameters of different groups.
All statistical calculations were performed using the statis-
tical package SPSS version 13.0 for Windows (SPSS, Inc.,
Chicago, IL). P < 0.05 was considered to be statistically
significant. For TCGA ovarian cancer RNA-Seq dataset,
a mean RPKM value of 4 was used as a cutoff.
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Additional file 1: Table S1. Primer sequences used in the study.
Table S1. lists all the primers for RT-PCR and bisulphite pyro-sequencing.
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